Clinical outcomes at 1 year in early Psoriasis Area and Severity Index responders compared with non-responders: Subgroup analysis of UNCOVER-3 trial.

Rosmarin, D; Smith, S; Shrom, D; Burge, R; See, K; McKean-Matthews, M; Ridenour, T; Lin, C-Y; Gorelick, J

Rosmarin, D; Smith, S; Shrom, D; Burge, R; See, K; McKean-Matthews, M; Ridenour, T; Lin, C-Y; Gorelick, J.

Afiliación

Rosmarin D; Tufts Medical Center Boston Massachusetts USA.
Smith S; California Dermatology and Clinical Research Institute Encinitas California USA.
Shrom D; Eli Lilly and Company Indianapolis Indiana USA.
Burge R; Eli Lilly and Company Indianapolis Indiana USA.
See K; Division of Pharmaceutical Sciences University of Cincinnati Cincinnati Ohio USA.
McKean-Matthews M; Eli Lilly and Company Indianapolis Indiana USA.
Ridenour T; Syneos Health Morrisville North Carolina USA.
Lin CY; Eli Lilly and Company Indianapolis Indiana USA.
Gorelick J; Eli Lilly and Company Indianapolis Indiana USA.

Skin Health Dis ; 1(3): e43, 2021 Sep.

Article en En | MEDLINE | ID: mdl-35663140

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Skin Health Dis Año: 2021 Tipo del documento: Article Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google